Pick Your Community: | Hopkins | Muhlenberg | Daviess | Christian | Henderson | Lakes | McCracken | Webster

FDA Approves New Drug for Advanced Prostate Cancer

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2014 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story by using one of the social media links below.

In Other News...

One Hospitalized, Another Jailed After Four-Car Collision

HENDERSON, Ky. (9/21/14) ― A multiple-vehicle accident occurred at 7 p.m. Saturday, Sept. 20 on the southbound bridge… Read More

Henderson County Police Reports

HENDERSON, Ky. (9/22/14) — The Henderson Police Department released the following reports. The Henderson Police… Read More

Most Read This Week (Site-Wide)

September 19, 2014 4695

Madisonville Man Among Three Arrested for…

in Top Stories by Muhlenberg Sheriff Curtis McGehee
September 20, 2014 3592

Large Cache of Drugs, Cash, Gun Seized;…

in Top Stories by MCSO PIO Alex Piper
September 17, 2014 3427

Wanted Man Leads Troopers on Chase…

in Top Stories by Trooper Stu Recke
September 18, 2014 3114

Hopkins County Grand Jury Indictments

in News by Karen McKnight
September 19, 2014 2848

Five Injured in Two-Vehicle Collision at…

in Top Stories by MPD Officer Russell Nichols

Most Read Stories from Hopkins County

September 17, 2014 3427

Wanted Man Leads Troopers on Chase…

in Top Stories by Trooper Stu Recke
September 19, 2014 2848

Five Injured in Two-Vehicle Collision at…

in Top Stories by MPD Officer Russell Nichols
September 18, 2014 1909

Manitou Man Charged with DUI

in Top Stories by Madisonville Police Department
September 18, 2014 1819

Vehicle Strikes CSX Train Cars at Crossing

in Top Stories by Trooper Stu Recke
September 22, 2014 1555

Man Arrested for Slashing Tires

in Top Stories by Madisonville Police Department

Most Read Stories from Owensboro

September 20, 2014 1114

Man Charged with Theft After KSP…

in Top Stories by Alexis McGee
September 19, 2014 893

STREET CLOSINGS FOR MONDAY, SEPTEMBER 22

in Top Stories by Abby Shelton
September 19, 2014 872

Police Searching for Hit-And-Run Driver

in Top Stories by Jennifer Smith, DCSO
September 18, 2014 699

Owensboro's Nathan Morris Has Worldwide…

in Top Stories by Paul McRee, SurfKY News
September 18, 2014 518

9-1-1 Phone Lines

in Top Stories by Michael Hathaway

Most Read Stories from Muhlenberg County

September 20, 2014 3592

Large Cache of Drugs, Cash, Gun Seized;…

in Top Stories by MCSO PIO Alex Piper
September 20, 2014 1676

Paradise NRA Banquet Promises Food, Fun,…

in Top Stories by Paul McRee, SurfKY News
September 22, 2014 1373

Third Suspect Charged in Greenville Home…

in Top Stories by MCITF PIO Wes Miller
September 22, 2014 836

Hundreds Turn Out for Greenville Festival

in Top Stories by Charles W. Riley II, SurfKY News
September 22, 2014 824

Muhlenberg Bass Team Members Score…

in Top Stories by Paul McRee, SurfKY News

SurfKY News Group, Inc. Central Office & Printing Division
1125 Nebo Rd.  •  Madisonville, KY 42431  •  270.452.2249 (fax)
Main Number: 270.452.2727 (phone)  •  Printing Division Direct Line: 270.821.8600 (phone)


Contact a member of our staff: www.surfky.com/contact
Copyright © 2014 SurfKY News Group, Inc.  •  Terms of Use  •  Site Map

social 03social 04social 22social 21social 06